MAPT and early-onset autosomal dominant Alzheimer disease: To this end, we employed two independent samples covering the entire AD spectrum, including 240 participants of the Alzheimer’s disease neuroimaging initiative (ADNI) and 57 subjects of the BioFINDER study for replication, all with available baseline amyloid-PET and longitudinal Flortaucipir tau-PET.